Powered by

Mirati Therapeutics Reports Second Quarter 2019 Financial Results

Aug 05, 2019 - PR Newswire
Board and Executive Moves

PR Newswire

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2019.

Second Quarter Highlights:

Initiated the Phase 3 randomized clinical trial, evaluating the combination of sitravatinib and nivolumab versus single-agent docetaxel, in second line patients with advanced non-squamous non-small cell lung cancer (NSCLC), following treatment with a first line, platinum-based re...